For instance, with first- and second-generation EGFR inhibitors, many EGFR-mutant NSCLC patients developed the T790M gatekeeper mutation, which hinders the drug from interacting with the kinase[82]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.